Victor J Kroon1,2, Steven W Mes3,4, Pepijn A Borggreven3, Rick van de Langenberg3, David R Colnot3, Jasper J Quak5. 1. Department of Otolaryngology and Head and Neck Surgery, Diakonessenhuis Utrecht, Bosboomstraat 1, 3582 KE, Utrecht, The Netherlands. v.j.kroon@students.uu.nl. 2. Faculty of Medicine, University Utrecht, Utrecht, The Netherlands. v.j.kroon@students.uu.nl. 3. Department of Otolaryngology and Head and Neck Surgery, Diakonessenhuis Utrecht, Bosboomstraat 1, 3582 KE, Utrecht, The Netherlands. 4. Otolaryngology-Head and Neck Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, Netherlands. 5. Department of Otolaryngology and Head and Neck Surgery, Diakonessenhuis Utrecht, Bosboomstraat 1, 3582 KE, Utrecht, The Netherlands. JQuak@diakhuis.nl.
Abstract
PURPOSE: To present the first pediatric study on the safety and efficacy of mastoid obliteration using S53P4 bioactive glass (BAG) for cholesteatoma surgery. METHODS: A single-center retrospective cohort study was conducted. Inclusion criteria were pediatric cases (≤ 18 years) and at least at least one year of follow-up including non-echo planar diffusion-weighted MRI to assess cholesteatoma recidivism. Both canal wall up (CWU) and canal wall down (CWD) procedures were evaluated. RESULTS: A total of 61 cases (56 patients) were included. Most cases had an otologic history before the development of the cholesteatoma. CWU procedure was performed in 18 cases (30%) and CWD procedure in 43 cases (70%). The cholesteatoma recidivism rate was 33% after a mean follow-up period of 58 months. Kaplan-Meier curve estimated a 5-year recidivism rate of 40%. Few complications were seen that were all minor and resolved spontaneously or after local or systemic treatment. Control of the infection (merchant grade 0-1) was achieved in 98% of the cases. Closure of the air-bone gap within 20 dB was achieved in 22% of the cases with complete audiometric evaluation. CONCLUSION: In this MRI-controlled study, we show the safety and efficacy of S53P4 BAG for mastoid obliteration in a pediatric cholesteatoma cohort. Postoperative complications were both rare and minor, and a dry ear was achieved in almost all patients. Nevertheless, persistent hearing loss and the apparent high recidivism rate reflect the challenging nature of pediatric cholesteatoma.
PURPOSE: To present the first pediatric study on the safety and efficacy of mastoid obliteration using S53P4 bioactive glass (BAG) for cholesteatoma surgery. METHODS: A single-center retrospective cohort study was conducted. Inclusion criteria were pediatric cases (≤ 18 years) and at least at least one year of follow-up including non-echo planar diffusion-weighted MRI to assess cholesteatoma recidivism. Both canal wall up (CWU) and canal wall down (CWD) procedures were evaluated. RESULTS: A total of 61 cases (56 patients) were included. Most cases had an otologic history before the development of the cholesteatoma. CWU procedure was performed in 18 cases (30%) and CWD procedure in 43 cases (70%). The cholesteatoma recidivism rate was 33% after a mean follow-up period of 58 months. Kaplan-Meier curve estimated a 5-year recidivism rate of 40%. Few complications were seen that were all minor and resolved spontaneously or after local or systemic treatment. Control of the infection (merchant grade 0-1) was achieved in 98% of the cases. Closure of the air-bone gap within 20 dB was achieved in 22% of the cases with complete audiometric evaluation. CONCLUSION: In this MRI-controlled study, we show the safety and efficacy of S53P4 BAG for mastoid obliteration in a pediatric cholesteatoma cohort. Postoperative complications were both rare and minor, and a dry ear was achieved in almost all patients. Nevertheless, persistent hearing loss and the apparent high recidivism rate reflect the challenging nature of pediatric cholesteatoma.
Authors: Eveliina Munukka; Outi Leppäranta; Mika Korkeamäki; Minna Vaahtio; Timo Peltola; Di Zhang; Leena Hupa; Heimo Ylänen; Jukka I Salonen; Matti K Viljanen; Erkki Eerola Journal: J Mater Sci Mater Med Date: 2007-06-14 Impact factor: 3.896
Authors: Jussi Sarin; Minna Vuorenmaa; Pekka K Vallittu; Reidar Grénman; Pia Boström; Pilvi Riihilä; Liisa Nissinen; Veli-Matti Kähäri; Jaakko Pulkkinen Journal: Otol Neurotol Date: 2021-06-01 Impact factor: 2.311
Authors: Bert De Foer; Jean-Philippe Vercruysse; Anja Bernaerts; Joachim Maes; Filip Deckers; Johan Michiels; Thomas Somers; Marc Pouillon; Erwin Offeciers; Jan W Casselman Journal: Neuroradiology Date: 2007-09-03 Impact factor: 2.804
Authors: Robert Nash; Phui Yee Wong; Ali Kalan; Ravi K Lingam; Arvind Singh Journal: Int J Pediatr Otorhinolaryngol Date: 2015-10-27 Impact factor: 1.675